Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Next Drug Price Revision Won’t Help Promote Generic Use, JGA President Says
January 9, 2014
- Japan CRO Association Announces Report on Quality Assurance of Subcontracted Services
January 9, 2014
- New Price Cut for Long-Listed Products “Harsh,” Needs Follow-Up Review: FPMAJ Chair Naito
January 1, 2014
- New Price Cut Rule for Long-Listed Products Will Wreak Havoc on Pharmas: FPMAJ Chair
December 27, 2013
- Osaka Bio Fund to Invest 150 Million Yen in Genomix
December 26, 2013
- Mr Koshimizu of MREAC Expresses Concern about Increasing Number of MSLs at a Seminar on Recertification of Managers in Charge of MR Education
December 24, 2013
- Sanofi’s Moulding Picked as New Chair of EFPIA Japan
December 17, 2013
- FPMAJ Chief Renews His Calls to Institutionalize Premium
December 16, 2013
- JPMA Revises Rules for Preparing Product Information Brochures for the 1st Time in 5 years; Bans “Emphasis on Differences” from and “Slander” of Competitors’ Products
December 13, 2013
- Head of JAMS COI Committee Proposes Legislating Ethical Guidelines for Clinical Research
December 11, 2013
- CSIMC Continues to Fire Barbs at “Precursor Premium” Despite Industry Appeal
December 10, 2013
- Mr Umeda of PhRMA Opposes Proposal to Revise Foreign Average Price Adjustment Rule
December 10, 2013
- JGA President Prefers 60% Rule for NHI Generic Prices, Fails to Gain Support on Five Generic Price Ranges
December 9, 2013
- Survey Finds that 1 in 4 MRs Still Smoke; Board Member of JSTC Calls Finding “Extremely Disappointing”
November 15, 2013
- JPA Express Deep Regrets over Decision on Lifting Online Sales Ban of OTC Drugs
November 11, 2013
- Mr Shirakawa of Kenporen Calls for New Look at Range of Drugs Eligible for Premium for New Drug Development
November 11, 2013
- Drug Damage Watchdog Presses Criminal Charge against Novartis over Diovan Ads
November 5, 2013
- JPMA Issues “Severe Warning” to MTPC for Violation of PAL Related to Medway Injection
November 1, 2013
- PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium
October 31, 2013
- Keizai Doyukai Recommends Measures to Ensure Adequate Funding for Proposed Japanese NIH
October 31, 2013
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…